Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Fibrotic lung disease inhibits immune responses to staphylococcal pneumonia via impaired neutrophil and macrophage function
Helen I. Warheit-Niemi, … , David N. O’Dwyer, Bethany B. Moore
Helen I. Warheit-Niemi, … , David N. O’Dwyer, Bethany B. Moore
Published January 6, 2022
Citation Information: JCI Insight. 2022;7(4):e152690. https://doi.org/10.1172/jci.insight.152690.
View: Text | PDF
Research Article Immunology Pulmonology

Fibrotic lung disease inhibits immune responses to staphylococcal pneumonia via impaired neutrophil and macrophage function

  • Text
  • PDF
Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by collagen deposition within the lung interstitium. Bacterial infection is associated with increased morbidity and more rapid mortality in IPF patient populations, and pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) are commonly isolated from the lungs of hospitalized patients with IPF. Despite this, the effects of fibrotic lung injury on critical immune responses to infection remain unknown. In the present study, we show that, like humans with IPF, fibrotic mice infected with MRSA exhibit increased morbidity and mortality compared with uninfected fibrotic mice. We determine that fibrosis conferred a defect in MRSA clearance compared with nonfibrotic mice, resulting from blunted innate immune responses. We show that fibrosis inhibited neutrophil intracellular killing of MRSA through impaired neutrophil elastase release and oxidative radical production. Additionally, we demonstrate that lung macrophages from fibrotic mice have impaired phagocytosis of MRSA. Our study describes potentially novel impairments of antimicrobial responses upon pulmonary fibrosis development, and our findings suggest a possible mechanism for why patients with IPF are at greater risk of morbidity and mortality related to infection.

Authors

Helen I. Warheit-Niemi, Summer J. Edwards, Shuvasree SenGupta, Carole A. Parent, Xiaofeng Zhou, David N. O’Dwyer, Bethany B. Moore

×

Figure 1

MRSA infection worsens outcome after fibrotic lung injury.

Options: View larger image (or click on image) Download as PowerPoint
MRSA infection worsens outcome after fibrotic lung injury.
(A) Mice were...
(A) Mice were treated with bleomycin or saline 14 days prior to infection with MRSA (7 × 107 CFU/mouse). Survival and weight loss were monitored for 7 days following infection. (B) Weight loss was monitored as a function of percentage of starting body weight in mice treated with bleomycin (n = 6), bleomycin + MRSA (n = 9), or saline + MRSA (n = 5) as described in A. Data from 1 experiment. Bars represent the means ± SD. Statistical analysis by mixed-effects analysis with Tukey’s multiple-comparison test. Statistical comparisons: **P < 0.01, ****P < 0.0001 bleomycin vs. bleomycin + MRSA; &P < 0.05, &&&P < 0.001 bleomycin vs. saline + MRSA; #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001 bleomycin + MRSA vs. saline + MRSA. X, death in bleomycin + MRSA group. (C) Survival was monitored daily in mice treated with bleomycin (n = 14), bleomycin + MRSA (n = 17), or saline + MRSA (n = 5) as described in A. Combined data from 2 independent experiments. Statistical analysis by log-rank test. *P < 0.05.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts